Brief: Labcorp Says Non-Human Primate Supply Issue To Negatively Impact Drug Development Revenue Between $80 Mln-$100 Mln Early In The Year - Conf. Call
Feb 16 (Reuters) - Laboratory Corporation of America
Holdings LH.N :
* LABCORP - NON-HUMAN PRIMATE SUPPLY ISSUE TO NEGATIVELY
IMPACT
DRUG DEVELOPMENT REVENUE BETWEEN $80 MILLION-$100 MILLION EARLY
IN THE YEAR - CONF. CALL
Further company coverage: LH.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Laboratory of America Holdings
See all newsBrief: Labcorp To Announce Second Quarter 2026 Financial Results On July 30, 2026
Brief: Labcorp And Epic Expand Collaboration To Advance Diagnostic Integration Across Hospitals And Health Systems
U.S. STOCKS ON THE MOVE-Quanta, O'Reilly Automotive, Avis
Labcorp lifts full‑year forecast as diagnostics business stays resilient (updated)
U.S. STOCKS ON THE MOVE-Qualcomm, Meta, Cardinal Health